Kenneth Alan Simmen,Herman Augustinus De Kock,Pierre Jean-Marie Bernard Raboisson,Lili Hu,Abdellah Tahri,Dominique Louis Nestor Ghislain Surleraux,Karl Magnus Nilsson,Bengt Bertil Samuelsson,Asa Annic
申请号：
US15454911
公开号：
US20170226111A1
申请日:
2017.03.09
申请国别(地区):
US
年份:
2017
代理人:
摘要：
Inhibitors of HCV replication of formula (I)and the N-oxides, salts, and stereoisomers, whereineach dashed line represents an optional double bond；X is N, CH and where X bears a double bond it is C；R1 is —OR7, —NH—SO2R8；R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl；R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, C3-7cycloalkyl；R4 is aryl or Het； n is 3, 4, 5, or 6；R5 is halo, C1-6alkyl, hydroxy, C1-6alkoxy, phenyl, or Het；R6 is C1-6alkoxy, or dimethylamino；R7 is hydrogen； aryl； Het； C3-7cycloalkyl optionally substituted with C1-6alkyl； or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het；R8 is aryl； Het； C3-7cycloalkyl optionally substituted with C1-6alkyl； or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het；aryl is phenyl optionally substituted with one, two or three substituents；Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, and being optionally substituted with one, two or three substituents；pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.
